CLINICAL TRIALS PROFILE FOR EVOBRUTINIB

Clinical Trials for Evobrutinib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02537028 ↗	MSC2364447C Phase 1b in Systemic Lupus Erythematosus	Completed	Merck KGaA	Phase 1	The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).
NCT02537028 ↗	MSC2364447C Phase 1b in Systemic Lupus Erythematosus	Completed	Merck KGaA, Darmstadt, Germany	Phase 1	The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).
NCT02537028 ↗	MSC2364447C Phase 1b in Systemic Lupus Erythematosus	Completed	EMD Serono Research & Development Institute, Inc.	Phase 1	The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).
NCT02784106 ↗	Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis	Completed	Merck KGaA	Phase 2	M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
NCT02784106 ↗	Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis	Completed	Merck KGaA, Darmstadt, Germany	Phase 2	M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
NCT02784106 ↗	Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis	Completed	EMD Serono Research & Development Institute, Inc.	Phase 2	M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
NCT02975336 ↗	A Phase II Study of M2951 in SLE	Terminated	Merck KGaA	Phase 2	M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).

Clinical Trial Conditions for Evobrutinib

Condition Name

Condition Name for
Intervention	Trials
Healthy	8
Relapsing-remitting Multiple Sclerosis	3
Relapsing Multiple Sclerosis	2
Rheumatoid Arthritis	2

Condition MeSH

Condition MeSH for
Intervention	Trials
Multiple Sclerosis	5
Sclerosis	5
Multiple Sclerosis, Relapsing-Remitting	3
Arthritis, Rheumatoid	2

Clinical Trial Locations for Evobrutinib

Trials by Country

Trials by Country for
Location	Trials
United States	81
Germany	18
Mexico	11
Japan	11
Argentina	8

Trials by US State

Trials by US State for
Location	Trials
Massachusetts	8
Florida	5
California	5
Texas	5
Arizona	4

Clinical Trial Progress for Evobrutinib

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	4
Phase 1	11

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	10
Active, not recruiting	3
Terminated	3

Clinical Trial Sponsors for Evobrutinib

Sponsor Name

Sponsor Name for
Sponsor	Trials
Merck KGaA, Darmstadt, Germany	11
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	10
EMD Serono Research & Development Institute, Inc.	9

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	38